Canada Administers First Alzheimer’s Infusion with New Drug

In a significant breakthrough for Alzheimer’s treatment, Sharon Runge has become the first patient in Canada to receive an infusion of Lecanemab, a drug recently approved by Health Canada. This historic moment marks a vital step forward for individuals living with Alzheimer’s disease and their families across the country.

Hope for Patients and Families

According to Dr. Sara Mitchell, a cognitive neurologist, the approval of Lecanemab represents a meaningful intervention in the fight against Alzheimer’s. The drug, which is a monoclonal antibody, targets and removes harmful amyloid plaques from the brain, a key factor in the progression of Alzheimer’s. Research indicates that Lecanemab can slow disease progression by approximately 30 percent.

Dr. Mitchell adds, “Longer-term data now tells us that up to four years of taking this drug extends out a one-year period of further independent living.” This extended independence is crucial for many families, as individuals with Alzheimer’s often face increasing reliance on their loved ones.

For Dallard Runge, Sharon’s husband, the approval of this drug brings a renewed sense of hope. “In the last year or so, Sharon was diagnosed with Alzheimer’s. My hope is that this drug delays the further onset of the disease for us. The longer we have together, the more happiness we’ll get to share,” he expresses.

Financial and Accessibility Challenges

While Lecanemab has received approval, it has not yet been funded by the Canada Drug Administration, leaving families like the Runges to cover the estimated annual cost of $32,000 for biweekly infusions, which varies based on the patient’s weight. Dr. Mitchell emphasizes the need for equitable access to this treatment, stating, “We are hoping that we can have equal access for all Canadians to this drug, and that requires government support.”

Despite the potential benefits, some public resistance has emerged regarding the allocation of taxpayer money for the expensive drug. Dallard Runge counters this perspective, urging, “I’d say they should walk in our shoes.” He reflects on the urgency of timely intervention, noting that Sharon began exhibiting early Alzheimer’s symptoms four years ago.

Medical professionals highlight that early intervention is essential, as harmful proteins associated with Alzheimer’s can accumulate in the brain long before symptoms manifest. The next phase of research will investigate whether Lecanemab can benefit asymptomatic individuals who harbor these problematic plaques.

Moments before receiving her historic infusion, Sharon shared her experience with CTV National News, expressing the difficulty in understanding her diagnosis. “In my day-to-day life, I feel like I’m fine,” she says, accompanied by a smile. Dallard notes that while her short-term memory has declined, her love and devotion to her family remain steadfast.

Sharon emphasizes her gratitude for her husband, stating, “I’m so fortunate to have met him; he’s the most important thing in my life.” The Runges now hold onto hope that this new treatment will allow them to cherish their time together longer, reinforcing the intrinsic value of life’s most precious moments.